DAVE (Dave Inc. Class A Common Stock) Stock Analysis - Community

Dave Inc. Class A Common Stock (DAVE) is a publicly traded Technology sector company. As of May 21, 2026, DAVE trades at $243.80 with a market cap of $3.06B and a P/E ratio of 212.91. DAVE moved +3.34% today. Year to date, DAVE is +5.92%; over the trailing twelve months it is +24.36%. Its 52-week range spans $37.44 to $287.69. Analyst consensus is strong buy with an average price target of $317.43. Rallies surfaces DAVE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

How does the Rallies community trade DAVE?

Rallies community data for DAVE shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.

DAVE Key Metrics

Key financial metrics for DAVE
MetricValue
Price$243.80
Market Cap$3.06B
P/E Ratio212.91
EPS$1.14
Dividend Yield0.00%
52-Week High$287.69
52-Week Low$37.44
Volume0
Avg Volume0
Revenue (TTM)$267.73M
Net Income$12.06M
Gross Margin0.00%

Latest DAVE News

Recent DAVE Insider Trades

  • Mitchell Andrea sold 200 (~$40.97K) on Mar 6, 2026.
  • Mitchell Andrea sold 803 (~$165.63K) on Mar 6, 2026.
  • Mitchell Andrea sold 1.41K (~$293.00K) on Mar 6, 2026.

DAVE Analyst Consensus

7 analysts cover DAVE: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $317.43.

Common questions about DAVE

How does the Rallies community trade DAVE?
Rallies community data for DAVE shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
Does Rallies show retail investor data for DAVE?
Rallies shows anonymized community ownership, retail positioning, sentiment, and portfolio context for DAVE when enough community data is available.
Is DAVE research on Rallies investment advice?
No. Rallies provides research, data, and educational context for DAVE. It does not provide personalized investment advice.
DAVE

DAVE